Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|Ships from British Columbia, Canada|Canadian Orders Ship Domestically, No Border Crossing|International Shipping Available|Lab Verified|≥98% Purity Guarantee|Shipped Within 24hr|Batch-Specific COAs|
HomeNewsRegulatory
Regulatory

BPC-157 + TB-500 Peptide Blend: Research on Healing and Repair

The BPC-157 and TB-500 peptide blend draws attention in research for potential synergy in tissue repair, angiogenesis, and reducing inflammation. BPC-157, a 15-amino-acid synthetic peptide, interacts with growth factors in preclinical models. TB-500, a 43-amino-acid analog of Thymosin Beta-4, supports cell migration and regeneration. Studies explore their roles in wound healing, tendon recovery, and more.

VP

Volta Peptides

Editorial Team

May 12, 2026Updated June 19, 20264 min read
BPC-157 + TB-500 Peptide Blend: Research on Healing and Repair

Key Takeaways

  • Research examines the combination of BPC-157 and TB-500 for possible benefits in speeding up healing processes, lowering inflammation levels, and improving tissue regeneration.
  • For detailed guidance, check the BPC-157 Research Guide and TB-500 Research Guide
  • BPC-157 serves as a synthetic pentadecapeptide from the Body Protection Compound.

Synergistic Potential in Tissue Regeneration

Research examines the combination of BPC-157 and TB-500 for possible benefits in speeding up healing processes, lowering inflammation levels, and improving tissue regeneration. BPC-157 consists of 15 amino acids, while TB-500 has 43 amino acids. These properties position the blend as a focus in laboratory studies on repair mechanisms.

For detailed guidance, check the BPC-157 Research Guide and TB-500 Research Guide.

Properties of BPC-157

BPC-157 serves as a synthetic pentadecapeptide from the Body Protection Compound. Preclinical studies investigate its effects on growth factors, blood vessel formation through angiogenesis, and pathways that control inflammation. Such work covers musculoskeletal systems, gastrointestinal functions, and vascular structures.

Scientists also note its potential cytoprotective qualities in joints, tendons, muscles, and nerves. Its chemical formula stands at C62H98N16O22, with a molecular weight of 1419.5 g/mol. Other names include Body Protection Compound-157.

Properties of TB-500

TB-500 acts as a synthetic version of Thymosin Beta-4 (Tβ4), featuring 43 amino acids from the TMSB4X gene. Laboratory research highlights its angiogenic effects, regenerative capabilities, and anti-inflammatory actions. Applications appear in areas like wound closure, neurological restoration, and general tissue mending.

It influences cell movement and motility while regulating actin dynamics. Studies connect it to microRNA-146a for anti-inflammatory effects. The formula is C212H350N56O78S, and its molecular weight reaches 4963 g/mol.

Chemical and Quality Considerations

Peptide blends like this undergo HPLC testing to confirm purity levels. Each batch includes a Certificate of Analysis (COA) for verification. Production follows controlled lab conditions, and storage maintains molecular stability.

Researchers benefit from tools like the Reconstitution Calculator and Purity Analyzer to handle such compounds accurately. Consistent quality supports reliable experimental outcomes.

Key Research Findings

Numerous studies underpin the interest in these peptides. For instance, Seiwerth, S., et al. (1997) explored BPC-157’s effect on healing in Journal of physiology, Paris vol. 91,3-5: 173-8. doi:10.1016/s0928-4257(97)89480-6. PMID: 9403790.

Chang, Chung-Hsun et al. (2011) reported on tendon healing in Journal of applied physiology vol. 110,3: 774-80. doi:10.1152/japplphysiol.00945.2010. PMID: 21030672.

Pevec D, et al. (2010) examined muscle healing in Med Sci Monit. 16(3):BR81-88. PMID: 20190676.

Sikiric, Predrag et al. (2016) discussed brain-gut axis implications in Current neuropharmacology vol. 14,8: 857-865.

For TB-500, Katherine M. Malinda et al. (1999) found it accelerates wound healing in Journal of Investigative Dermatology, Volume 113, Issue 3: 364-368.

Xu B, et al. (2013) noted ligament injury benefits in Regul Pept. 184:1-5. doi: 10.1016/j.regpep.2013.03.026. PMID: 23523891.

A clinical trial on Thymosin Beta 4 for pressure ulcers appears at NCT00382174.

Additional Supporting Studies

Keiwerth, S., et al. (2021) covered stable gastric pentadecapeptide BPC 157 in Frontiers in pharmacology, 12, 627533. doi:10.3389/fphar.2021.627533.

Maar, K., et al. (2021) addressed Thymosin Beta-4 in anti-aging therapies in Cells, 10(6), 1343. doi:10.3390/cells10061343.

National Center for Biotechnology Information provides PubChem data: CID 132558700 and CID 9941957.

Gurtner GC, et al. (2008) reviewed wound repair in Nature. 453(7193):314-21. doi: 10.1038/nature07039. PMID: 18480812.

Santra, M., et al. (2014) linked Thymosin β4 to microRNA-146a in The Journal of biological chemistry, 289(28): 19508, 19518. doi:10.1074/jbc.M113.529966.

Srivastava, D., et al. (2012) explored cardiac repair in Annals of the New York Academy of Sciences, 1270: 66, 72. doi:10.1111/j.1749-6632.2012.06696.x.

Bock-Marquette, I., et al. (2004) detailed cardiac effects in Nature, 432(7016): 466, 472. doi:10.1038/nature03000.

Research Use Guidelines

These peptides suit laboratory and scientific research exclusively. They lack approval from Health Canada and cannot support human or veterinary use, therapy, or self-dosing. Descriptions draw from experimental literature and preclinical data, offering information without medical claims or proof of safety and efficacy.

Unauthorized products face risks outside research settings. Use the Peptide Glossary or Interaction Checker for precise handling. Anecdotal notes include: "spray really surprised me! I was skeptical at first, but this nasal spray really surprised me! I’ve been struggling with shoulder pain and discomfort for years... Definitely a game-changer!" and "Dealing with seven herniated and two stenosis has been challenging, but this product has truly".

Looking for high-purity research peptides? Browse our catalog for HPLC-verified compounds.

CompoundPuritySizePrice
BPC-157 5mg≥98%5mg$34.00
TB-500 5mg≥98%5mg$29.00
BPC-157 10mg≥98%10mg$44.00

Browse Full Catalog →

Research Use Only. This article is provided for informational and educational purposes only. The compounds and topics discussed are intended solely for laboratory and scientific research. This content does not constitute medical advice, and Volta Peptides does not endorse or promote human consumption of any research compound.

More from Volta Peptides

General

BPC-157 News: FDA Advisers Weigh Easing Restrictions on Six Peptides

FDA advisers have reportedly supported easing restrictions on six peptides, a move that could reshape the peptide research landscape. While BPC-157 and TB-500 were not explicitly named, the decision signals growing regulatory attention. Here's what researchers and industry professionals should know.

Jul 31· min read
Regulatory

FDA Peptide Vote Explained: Why These Drugs Await Approval

A recent FDA advisory vote has left many peptide-based drugs unapproved, raising questions about the regulatory path forward. This article explains the vote's context, the reasons behind the delay, and what it means for developers and patients.

Aug 4· min read
Regulatory

Roche Secures CE Mark for Second Eli Lilly Alzheimer’s Test

Roche has obtained a European CE mark for its second Alzheimer’s test developed with Eli Lilly. The diagnostic can confirm the disease or rule it out. This approval enables use across Europe for better patient assessment.

May 13· min read
Regulatory

FDA Urged to Reject Untested Peptides in Compounded Medications

The Information Technology and Innovation Foundation (ITIF) published a blog on July 22, 2026, arguing that the FDA should not allow untested peptides to be added into patients' medications. The piece warns that adding unapproved peptides to compounded drugs poses serious safety risks without proven benefits, and calls for stronger regulatory oversight to protect public health.

Jul 23· min read
Science

Penn Study: Inconsistent GLP-1 Use May Cause Weight Gain

Researchers at the University of Pennsylvania discovered that intermittent use of GLP-1 drugs like semaglutide in mice led to weight gain and fat accumulation. The study from Penn's Leung Lab showed reduced drug effectiveness after cycling on and off the medication. About one in eight adults use these drugs for weight loss, but over half stop within two years and often restart.

May 15· min read
Regulatory

Eli Lilly Sets Retatrutide FDA Filing Date; Stock Target Questioned

Eli Lilly has locked in a U.S. Food and Drug Administration (FDA) filing date for its investigational obesity drug retatrutide, according to a recent report. The news has sparked analyst discussion about whether the company's stock could reach $1,750 by 2027. The filing date marks a key regulatory milestone for the potential blockbuster therapy.

Aug 8· min read

Your Cart

Your cart is empty

Browse our catalog to add research compounds.